Evidence map›Paper›PMID 42864335›Full record

ArticleNature communications2026

Structural basis of IgLON5 autoantibody recognition in autoimmune encephalitis.

Angelique Roux, Rachel Schelling, David Vinyals-Sales, Lidia Sabater, Rahel R Winiger, Ilayda Senyuz, Alison Lin, Amandine Mathias, Renaud Du Pasquier, Carles Gaig and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Angelique Roux *Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Rachel Schelling *Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-6966-6626
David Vinyals-Sales *Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Lidia SabaterNeuroimmunology Program, Fundació de Recerca Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer; and Caixa Research Institute (CRI), Universitat de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Rahel R WinigerDepartment of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-9796-5543
Ilayda SenyuzLaboratory of Neuroimmunology, Neuroscience Research Centre, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Alison LinDepartment of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Amandine MathiasLaboratory of Neuroimmunology, Neuroscience Research Centre, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0009-0005-3604-5096
Renaud Du PasquierLaboratory of Neuroimmunology, Neuroscience Research Centre, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2786-3434
Carles GaigMultidisciplinary Sleep Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain. Neurology Service, Hospital Clinic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-7113-8125
Josep DalmauNeuroimmunology Program, Fundació de Recerca Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer; and Caixa Research Institute (CRI), Universitat de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.ORCID http://orcid.org/0000-0001-5856-2813
Mathilde FoglieriniDepartment of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-7538-4262
Laurent PerezDepartment of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. laurent.perez@chuv.ch.ORCID http://orcid.org/0000-0002-8860-7928

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 10005403
6 · The paper itself

Abstract

Anti-IgLON5 disease is a rare neuro-immunological disorder characterized by autoantibodies targeting the neuronal adhesion molecule IgLON5, as well as profound brain dysfunction and tau pathology. Despite its severe clinical manifestations, the molecular basis of antibody recognition and its contribution to disease pathogenesis is poorly understood. Here, we characterize the B cell receptor repertoire of a patient with anti-IgLON5 disease, revealing marked diversity and no evidence of dominant clonal expansion. We isolate a human monoclonal IgG4 antibody that binds IgLON5 with high affinity and determine the structure of its Fab in complex with IgLON5 using cryo-electron microscopy. Biochemical and structural analyses show that antibody binding preserves IgLON5 adhesive interfaces while remaining compatible with clustering of IgLON5 on the cell surface. Analysis of the germline-reverted precursor suggests that IgLON5 recognition is already present before affinity maturation and is strengthened by somatic mutations that stabilize antigen binding. These findings provide mechanistic insight into autoantibody recognition of neuronal surface proteins and establish a framework for understanding antibody-mediated neurodegeneration in anti-IgLON5 disease.

Indexed as

AutoantibodiesCell Adhesion Molecules, NeuronalEncephalitisHashimoto DiseaseAnimalsAntibodies, MonoclonalB-LymphocytesCryoelectron MicroscopyHumansImmunoglobulin Fab FragmentsImmunoglobulin GAntibodies, MonoclonalAutoantibodiesCell Adhesion Molecules, NeuronalIgLON5 protein, humanImmunoglobulin Fab FragmentsImmunoglobulin G

Identifiers

PMID42864335
PMCPMC13658817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.